Neoadjuvant and adjuvant immunotherapy in early-stage non-small cell lung cancer

N Shukla, N Hanna - Lung Cancer: Targets and Therapy, 2021 - Taylor & Francis
Surgery or concurrent chemoradiation are standard of care treatments for patients with
localized and locally advanced non-small cell lung cancer (NSCLC). While resection and
chemoradiation are potentially curative therapies for early-stage disease, relapse rates
remain high. Adjuvant or neoadjuvant chemotherapy improves cure rates 5–15% compared
with surgery alone for patients with resectable disease. Immune checkpoint inhibitors (ICI)
have heralded a new era for the treatment of advanced NSCLC with one-third of patients …

[HTML][HTML] Neoadjuvant and adjuvant immunotherapy in early-stage non-small-cell lung cancer, past, present, and future

CH Szeto, W Shalata, A Yakobson… - Journal of Clinical …, 2021 - mdpi.com
Lung cancer is worldwide the most common malignancy. Standard of care treatments for
early-stage non-small-cell lung cancer (NSCLC) include surgery and adjuvant
chemotherapy. However, these patients continue to have poor prognosis due to systemic or
local relapse. Immunotherapy has been considered as a novel approach to improve survival
in patients with early-stage NSCLC. Since immune checkpoint inhibitors have transformed
the treatment of advanced NSCLC, there is a growing interest in the role of immunotherapy …
以上显示的是最相近的搜索结果。 查看全部搜索结果